

Lupin Group Company

 Phone:
 61 3 9809 7900

 Fax:
 61 3 9809 7999

 Address:
 Suite 2, Level 2, 19-23 Prospect Street, Box Hill, Vic 3128

 Web:
 www.generichealth.com.au

 ABN:
 93 110 617 859

Teriflunomide GH Prescriber/Healthcare Professional Checklist

Patient Name:

Therapy Start Date:

ROUTINE MONITORING RECOMMENDED

Before starting Teriflunomide GH therapy:

- Check transaminase and bilirubin levels (within 6 months before starting therapy).
- Exclude pregnancy and confirm use of effective contraception.
- Counsel patients on the potential for serious risk to the foetus and use of effective contraception in females of reproductive potential.
- Obtain a complete blood count (CBC) (within 6 months before starting therapy).
- Screen for latent tuberculosis infection.
- Check baseline blood pressure.

During Teriflunomide GH therapy:

- Monitor alanine aminotransferase (ALT) levels monthly (for 6 months).
- Check blood pressure periodically.
- Counsel patients to continue use of effective contraception during therapy.

TERIFLUNOMIDE GH is contraindicated in:

- patients with severe hepatic impairment;
- pregnant women;
- females of reproductive potential who are not using effective contraception;
- patients with a history of hypersensitivity to teriflunomide, its inactive ingredients or leflunomide, or who are currently taking leflunomide.

Prescribers/Healthcare Professionals can request further copies of the checklist from Generic Health Pty Ltd. To access or download, visit: <u>https://www.generichealth.com.au/</u>



